AiXin Life hit by 61% revenue drop, margin collapse and going-concern warning

AiXin Life International, Inc. (PINK: AIXN)

Quick take - what's happening inside: management is wrestling with a sharp revenue decline, heavy operating losses across all segments, and a large working-capital shortfall that's being bridged mainly by related‑party financing and one‑time non‑operating gains. The SEC 10‑Q flags a going‑concern and material weaknesses in controls.

Key facts & figures
- Total revenue (6 months ended June 30, 2025): $859,760 vs $2,184,209 a year earlier (down 61%).
- Net loss (6 months): $1,073,213 vs $780,383 (2024). Loss per share (6 months): $(0.043).
- Net loss (quarter ended June 30, 2025): $351,505; loss per share (quarter): $(0.014).
- Total assets (June 30, 2025): $3,346,709; total liabilities: $8,796,650.
- Stockholders' deficit: $(5,449,941) (June 30, 2025).
- Cash and equivalents: $29,621 (down from $62,310 at 12/31/24).
- Working capital deficit: $6,423,194 (as of June 30, 2025).
- Due to related parties: $4,541,916 (June 30, 2025).
- Accounts receivable (total current): $118,847; accounts receivable - related parties: $440,824.
- Operating lease liabilities: total $1,391,927 (current $179,134; non‑current $1,212,793).
- One customer concentration: 44% of revenue in the three and six months ended June 30, 2025 (net sales $203,725 and $381,638 respectively).
- Major supplier concentration (six months): Supplier A = $166,615 (29%); Supplier D = $59,992 (11%).
- Government grant balance: $310,062 (company indicates plan to return funds; $432,188 returned in the six months).
- Shares outstanding (as of Aug 19, 2025): 24,999,834.

Positive points (income‑statement / cash flow)
- Significant non‑operating other income of $481,102 in the six months (gain on disposal of fixed assets) reduced the headline loss - non‑operating income, net was $420,945 (6 months).
- Company reduced some operating expense items YoY (stock‑based compensation was $0 in 2025 vs $185,770 in H1 2024; depreciation & amortization decreased).
- Financing inflows: advances from related parties provided $2,301,491 during the six months, helping cover cash shortfall (net cash provided by financing activities: $1,128,327).
- Inventory reserve stable: ending inventory reserve $90,574 (June 30, 2025) vs $89,349 (12/31/24).

Negative points (income‑statement / business risks)
- Severe revenue collapse across all product segments: Direct sales down ~90% YoY, Pharmacies down ~87-90%, Manufacture & Sale down 38-51% depending on period - overall revenue fell ~61-65% year over year.
- Gross margin deterioration in manufacturing: manufacture & sale cost of sales was 101% of revenue for six months (costs exceed sales), indicating unit economics breakdown and fixed cost absorption problems.
- Large and growing operating losses: loss from operations $1,493,109 (six months) and $810,624 (quarter) - operating costs remain far above revenues.
- Cash burn: net cash used in operating activities $1,150,477 in six months; cash balance now only $29,621 - limited runway without new funding.
- Heavy reliance on related‑party funding and large related‑party balances (due to related parties $4.54M), concentrating governance and liquidity risk.
- Customer concentration: single customer = 44% of revenue - loss of that customer would materially damage revenue.
- Going concern: auditors/management explicitly state facts and conditions raise substantial doubt about ability to continue as a going concern.
- Controls: disclosure controls deemed not effective; material weaknesses in internal control over financial reporting noted.
- Stockholders' deficit: negative equity of $(5.45M) increases risk of capital raising/dilution and limits financing options.

Operational highlights by segment
- Manufacture & Sale remains the largest revenue driver (64% of H1 2025 revenue) but margin is broken (costs ~101% of revenue in H1).
- Hotel revenue fell (H1 2025: $193,083 vs $274,562) but represents a larger share of total revenue (22% in H1 2025). Hotel operating costs remain high ($525,202 for H1).
- Pharmacies and direct sales volumes collapsed, reflecting weakness in retail/marketing effectiveness and competition from online channels.

What to watch next (near‑term catalysts & risks)
- Liquidity moves: whether related‑party advances continue or the company secures external financing or equity raises.
- Execution of management's liquidity plan (cost cuts, higher margin sales) and any formal restructuring of operations.
- Changes in related‑party balances or material related‑party transactions (large exposures to CEO/insiders).
- Any remediation of internal control weaknesses and improved disclosure timing.
- Customer/supplier concentration shifts (loss of major customer or supplier disruption would be severe).

Bottom line: AiXin Life (PINK: AIXN) faces a steep revenue downturn and structural margin issues in manufacturing that have produced large operating losses and a serious working‑capital hole. One‑time gains and related‑party financing are keeping it afloat for now, but the company has limited cash, negative equity, and a going‑concern warning - investors should treat the equity as high‑risk and monitor liquidity, related‑party funding, and margin recovery closely.